RBC Capital Markets has lowered its price target for Smith & Nephew, the London-listed medical technology company, to £11.50 from £12.50, following another reduction in the firm's full-year 2026 growth outlook. The bank's move comes after Smith & Nephew trimmed its underlying revenue growth guidance for 2026 to roughly 3%, down from a previous forecast of 4% and well below the 6% it had originally targeted at the start of the year.
The repeated downgrades have raised concerns among analysts that the company's forecasts may be less reliable than previously thought, and that execution risks are higher than management had signaled. RBC's updated assessment, issued after Smith & Nephew's third-quarter results, reflects a more cautious view on the company's near-term prospects.
What's behind the guidance cuts?
Smith & Nephew, which makes orthopedic implants, wound care products, and sports medicine devices, has faced a series of challenges that have weighed on its growth. The company's guidance has been trimmed twice this year, first from 6% to 4% in August, and now to about 3%. This pattern of downward revisions is often seen as a red flag by investors, as it suggests that the company's earlier expectations were too optimistic.
RBC specifically pointed to several areas of concern. The bank said it wants clearer evidence that the newly launched LANDMARK cementless hip replacement system is gaining traction with surgeons. A cemented version of the product is not expected until the second quarter of 2027, which could limit near-term adoption. RBC also flagged uncertainty from China's volume-based procurement program, which has pressured pricing in the company's Sports Medicine business, and noted that the skin-substitute market is normalizing more slowly than expected.
These headwinds have led RBC to lower its sales growth forecasts for 2026 through 2029 and to cut its core earnings-per-share outlook. Despite these reductions, the bank maintained its “sector perform” rating, indicating that it sees the stock as fairly valued relative to its peers.
What's going well?
Not all the news is negative. RBC acknowledged that several of Smith & Nephew's segments are performing well, and it pointed to the company's strategic review of its orthopedics unit as a sign that management is focused on improving shareholder value. The review could lead to divestitures or other structural changes that might unlock value.
Still, the analysts are waiting for a cleaner “reset” from the company, starting with a conservative 2027 outlook. A more cautious guidance for next year could help rebuild credibility with investors, who have been burned by repeated downgrades.
What it means for investors
For everyday investors, the key takeaway is that a single guidance trim can be dismissed as bad timing, but a step-down from 6% to 4% to about 3% is harder to ignore. When a company repeatedly lowers its forecasts, analysts often assume that its estimates are less dependable and that execution risk is higher than previously believed.
This can weigh on valuations in two ways. First, earnings estimates come down, as RBC's lower growth and profit forecasts demonstrate. Second, the valuation multiple—the price investors are willing to pay for each dollar of earnings—can shrink because the range of possible outcomes feels wider. In other words, the stock may trade at a lower price-to-earnings ratio than it would if the company had a steadier track record.
Until Smith & Nephew shows more consistent delivery, targets like £11.50 can behave less like a midpoint estimate and more like a near-term cap. A clearer 2027 guide, along with evidence that newer products are gaining traction with surgeons and that China-related headwinds are manageable, is what typically reduces that discount.
For context, other companies have faced similar credibility challenges after cutting guidance. For example, UBS recently warned that Aramark's 2027 growth guidance may disappoint investors, highlighting how forward-looking statements can shape market expectations. Similarly, Merck KGaA raised its 2026 profit target again after a solid third quarter, showing how positive revisions can boost confidence. In contrast, Recruit's AI hiring tools drove a 64% profit jump and lifted guidance, underscoring the market's preference for companies that deliver upside surprises.
Investors should watch for Smith & Nephew's next earnings report and any updates on its strategic review. The company's ability to meet or beat its revised 2026 targets will be crucial in determining whether the stock can recover from its recent setbacks.
